Furthermore, mutations in the ACTN4 and synaptopodin promoters have been found in patients and these mutations are associated with reduced promoter activity[51], suggesting that loss of nephrin, ACTN4 or synaptopodin expression may contribute to FSGS. Here, SYNPO is linked to focal segmental glomerulosclerosis.